Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Lexaria Bioscience ( (LEXX) ) just unveiled an update.
Lexaria Bioscience Corp. has announced the completion of initial pre-clinical studies under a Material Transfer Agreement with a pharmaceutical company, focusing on its DehydraTECH technology. While results from these studies will not be disclosed, the pharmaceutical partner has expressed interest in reviewing upcoming safety and efficacy data from Lexaria’s ongoing human study in Australia. The collaboration may extend to human clinical trials, with the parties maintaining their relationship under the current agreement until further data becomes available.
The most recent analyst rating on (LEXX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, specializing in its patented DehydraTECH technology. This technology enhances the oral delivery of drugs by improving bio-absorption, reducing side effects, and facilitating drug passage across the blood-brain barrier. The company operates a licensed research laboratory and holds a strong intellectual property portfolio with numerous patents.
Average Trading Volume: 111,063
Technical Sentiment Signal: Sell
Current Market Cap: $21.04M
See more data about LEXX stock on TipRanks’ Stock Analysis page.